Milestone Pharmaceuticals(US:MIST) Globenewswire·2026-03-31 12:00Core Viewpoint - Milestone Pharmaceuticals has successfully expanded access to its product CARDAMYST™ (etripamil) nasal spray through its inclusion in Express Scripts' national formularies, enhancing affordability and accessibility for patients with paroxysmal supraventricular tachycardia (PSVT) across the United States [1][3]. Company Overview - Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines, with CARDAMYST as its lead product [16]. - The company aims to provide effective treatment options for patients suffering from heart conditions, particularly PSVT [16]. Product Information - CARDAMYST is the first FDA-approved self-administered nasal spray for converting acute symptomatic episodes of PSVT to sinus rhythm in adults [2][5]. - The product is designed as a rapid response therapy, allowing patients to manage their condition without immediate medical oversight [5]. - CARDAMYST has undergone a robust clinical trial program, including a completed Phase 3 clinical-stage program for PSVT treatment [5]. Market Impact - The addition of CARDAMYST to Express Scripts' formularies marks a significant milestone as it is the first major payor to accept the product, which is expected to improve patient access to this treatment option [3]. - Approximately two million people in the U.S. are diagnosed with PSVT, indicating a substantial market potential for CARDAMYST [4]. Future Development - Milestone Pharmaceuticals is committed to further expanding access to CARDAMYST and is actively engaging with other insurance providers to increase coverage [3]. - Etripamil, the active ingredient in CARDAMYST, is also in development for treating PSVT in pediatric patients and for controlling acute atrial fibrillation with rapid ventricular rate in adults [5].